OnKure Therapeutics (NASDAQ:OKUR) Announces Quarterly Earnings Results

OnKure Therapeutics (NASDAQ:OKUR) released its quarterly earnings results on Thursday. The company reported ($0.99) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.16, FiscalAI reports.

OnKure Therapeutics Trading Down 0.3%

Shares of NASDAQ OKUR traded down $0.01 during mid-day trading on Thursday, hitting $3.52. The company had a trading volume of 96,864 shares, compared to its average volume of 113,119. The company has a market capitalization of $47.69 million, a PE ratio of -0.73 and a beta of 0.45. The firm has a 50-day simple moving average of $2.81 and a two-hundred day simple moving average of $2.86. OnKure Therapeutics has a one year low of $1.70 and a one year high of $5.28.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of OnKure Therapeutics in a report on Monday, December 22nd. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, OnKure Therapeutics has an average rating of “Hold” and a consensus target price of $34.00.

Institutional Trading of OnKure Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of OKUR. XTX Topco Ltd bought a new position in OnKure Therapeutics in the second quarter valued at approximately $25,000. Jane Street Group LLC acquired a new position in shares of OnKure Therapeutics during the 4th quarter worth approximately $56,000. Rangeley Capital LLC bought a new stake in shares of OnKure Therapeutics during the 2nd quarter worth approximately $71,000. Barclays PLC raised its stake in shares of OnKure Therapeutics by 4,286.8% during the 4th quarter. Barclays PLC now owns 27,242 shares of the company’s stock worth $79,000 after purchasing an additional 26,621 shares in the last quarter. Finally, Kotler Kevin acquired a new stake in shares of OnKure Therapeutics in the 4th quarter valued at approximately $573,000. Institutional investors own 90.98% of the company’s stock.

About OnKure Therapeutics

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.